Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which engages in the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. It also delivers off-the-shelf treatments to patients with high unmet medical need. Its product pipeline includes Tab-cel, ATA188, ATA2271/ATA3271, and ATA3219. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in Thousand Oaks, CA. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Touchon Pascal | President and CEO | May 16 '24 | Sale | 0.62 | 81,506 | 50,289 | 1,829,146 | May 20 08:34 PM | Nguyen AnhCo | EVP, Chief Sci. & Tech Officer | May 16 '24 | Sale | 0.62 | 42,899 | 26,469 | 898,498 | May 20 08:34 PM | Murugan Amar | EVP, Chief Legal Officer | May 16 '24 | Sale | 0.62 | 32,401 | 19,991 | 695,120 | May 20 08:33 PM | Hyllengren Eric J | EVP, CFO | May 16 '24 | Sale | 0.62 | 28,648 | 17,676 | 645,671 | May 20 08:33 PM | Henrich Jill | EVP, Global Head RA & Quality | May 16 '24 | Sale | 0.62 | 25,750 | 15,888 | 529,251 | May 20 08:32 PM | Touchon Pascal | President and CEO | Mar 04 '24 | Sale | 0.72 | 24,844 | 17,888 | 1,910,652 | Mar 06 06:19 PM | Nguyen AnhCo | EVP, Chief Sci. & Tech Officer | Mar 04 '24 | Sale | 0.72 | 10,746 | 7,737 | 941,397 | Mar 06 06:18 PM | Murugan Amar | EVP, Chief Legal Officer | Mar 04 '24 | Sale | 0.72 | 10,044 | 7,232 | 727,521 | Mar 06 06:18 PM | Henrich Jill | EVP, Global Head RA & Quality | Mar 04 '24 | Sale | 0.72 | 3,879 | 2,793 | 555,001 | Mar 06 06:16 PM | Touchon Pascal | President and CEO | Nov 16 '23 | Sale | 0.39 | 20,409 | 7,939 | 655,496 | Nov 20 05:31 PM | Joshi Manher | EVP, Chief Medical Officer | Nov 16 '23 | Sale | 0.39 | 12,287 | 4,780 | 171,284 | Nov 20 05:30 PM | Hyllengren Eric J | SVP, CFO | Nov 16 '23 | Sale | 0.39 | 11,958 | 4,652 | 205,998 | Nov 20 05:29 PM | Nguyen AnhCo | EVP, Chief Sci. & Tech Officer | Nov 16 '23 | Sale | 0.39 | 8,856 | 3,445 | 277,143 | Nov 20 05:31 PM | Murugan Amar | EVP, Chief Legal Officer | Nov 16 '23 | Sale | 0.39 | 8,307 | 3,231 | 257,084 | Nov 20 05:30 PM | Henrich Jill | EVP, Global Head RA & Quality | Nov 16 '23 | Sale | 0.39 | 3,267 | 1,271 | 104,424 | Nov 20 05:29 PM | Gallagher Carol Giltner | Director | Nov 14 '23 | Buy | 0.31 | 90,980 | 28,186 | 459,418 | Nov 15 05:07 PM | Gallagher Carol Giltner | Director | Nov 13 '23 | Buy | 0.22 | 179,020 | 40,029 | 368,438 | Nov 15 05:07 PM | DOBMEIER ERIC | Director | Nov 10 '23 | Buy | 0.23 | 446,825 | 101,340 | 563,325 | Nov 14 06:27 PM | HEIDEN WILLIAM K | Director | Nov 10 '23 | Buy | 0.25 | 100,000 | 25,330 | 209,000 | Nov 14 06:29 PM | Touchon Pascal | President and CEO | Aug 16 '23 | Sale | 1.65 | 30,766 | 50,835 | 675,905 | Aug 18 06:25 PM | Nguyen AnhCo | EVP, Chief Sci. & Tech Officer | Aug 16 '23 | Sale | 1.65 | 15,126 | 24,997 | 285,999 | Aug 18 06:25 PM | Murugan Amar | EVP, Chief Legal Officer | Aug 16 '23 | Sale | 1.65 | 8,672 | 14,330 | 265,391 | Aug 18 06:25 PM | Hyllengren Eric J | SVP, CFO | Aug 16 '23 | Sale | 1.65 | 8,186 | 13,527 | 217,956 | Aug 18 06:25 PM | Joshi Manher | EVP, Chief Medical Officer | Aug 16 '23 | Sale | 1.65 | 6,975 | 11,526 | 183,571 | Aug 18 06:25 PM | Henrich Jill | EVP, Global Head RA & Quality | Aug 16 '23 | Sale | 1.65 | 3,346 | 5,531 | 107,691 | Aug 18 06:25 PM | Touchon Pascal | President and CEO | Jun 27 '23 | Sale | 1.66 | 14,291 | 23,723 | 706,671 | Jun 29 04:15 PM |
|